For example, studies have reported that ACAT1 (cholesterol acyltransferase 1) in subpathways 00640_1 (propanoate metabolism) and 00900_1 (terpenoid backbone biosynthesis) may be a therapeutic target for the treatment of GBM (34). This evidence concerns the gene SOAT1 and glioblastoma.